It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…
Category Archives: venture captial
Biotech Fundraising Slows in 1H12, Tougher Times Ahead?
July 9, 2012 – 11:35 am
There is no doubt that 2011 was a hot financing year for biotech and it was always going to be a tough act to follow.
Profit vs. Value: When Activist Shareholders Attack
April 11, 2012 – 3:09 pm
Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…
Biotech Fundraising Dips in Q112, But No Need to Panic
April 10, 2012 – 10:48 am
I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year.
Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?
March 15, 2012 – 10:46 am
The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire.
He Said What?!?! Best Biotech Quotes of 2011
December 29, 2011 – 3:26 pm
As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…
Send Me an Angel: More VC Alternatives on the Rise
November 28, 2011 – 10:30 am
It seems to me that an increasing number of start-ups have been boot-strapping their way through preclinical without venture capital lately.
Join the Conversation